Corpus overview


MeSH Disease

Human Phenotype


There are no transmission terms in the subcorpus

    displaying 1 - 3 records in total 3
    records per page

    Incidence and risk factors of kidney impairment on patients with COVID-19: a systematic review and meta-analysis

    Authors: Qixin Yang; Xiyao Yang

    doi:10.1101/2020.05.28.20116400 Date: 2020-06-03 Source: medRxiv

    Background: The novel coronavirus is pandemic around the world. Several researchers have given the evidence of impacts of COVID-19 on the respiratory, cardiovascular and gastrointestinal system. Studies still have debated on kidney injury of COVID-19 patients. The purpose of the meta-analysis was to evaluate the association of kidney impairment with the development of COVID-19. Methods: The PubMed, Embase and MedRxiv databases were searched until April 1, 2020. We extracted data from eligible studies to summarize the clinical manifestations and laboratory indexes of kidney injury on COVID-19 infection MESHD patients and further compared the prevalence SERO of acute kidney injury MESHD acute kidney injury HP (AKI) and the mean differences of three biomarkers between in ICU/severe and non-ICU/non-severe cases. Heterogeneity was evaluated using the I2 method. Results: In the sum of 19 studies with 4375 patients were included in this analysis. The pooled prevalence SERO of AKI, increased serum SERO creatinine (Scr), increased blood urea nitrogen HP blood SERO urea nitrogen (BUN), increased D-dimer, proteinuria MESHD proteinuria HP and hematuria MESHD hematuria HP in patients with COVID-19 were 7.7%, 6.6%, 6.2%, 49.8%, 42% and 30.3% respectively. Moreover, the means of Scr, BUN and D-dimer were shown 6-folds, 1.8-folds and 0.68-folds, respectively, higher in ICU/severe cases than in corresponding non-ICU/non-severe patients. The prevalence SERO of AKI was about 17 folds higher in ICU/severe patients compared with the non-ICU/non-severe cases. Conclusions: Overall, we assessed the incidences of the clinic and laboratory features of kidney injury in COVID-19 patients. And kidney dysfunction may be a risk factor for COVID-19 patients developing into the severe condition. In reverse, COVID-19 can also cause damage to the kidney.

    Risk stratification of hospitalized COVID-19 patients through comparative studies of laboratory results with influenza

    Authors: Yang Mei; Samuel E Weinberg; Lihui Zhao; Chao Qi; Adam Frink; Amir Behdad; Peng Ji

    doi:10.1101/2020.05.18.20101709 Date: 2020-05-22 Source: medRxiv

    Background The outbreak of coronavirus disease MESHD 2019 (COVID-19) in December 2019 overlaps with the flu season. Methods We compared clinical and laboratory results from 719 influenza and 973 COVID-19 patients from January to April 2020. We compiled laboratory results from the first 14 days of the hospitalized patients using parameters that are most significantly different between COVID-19 and influenza and hierarchically clustered COVID-19 patients based on these data. The clinical outcomes were compared among different clusters. Results Temporal analyses of laboratory results revealed that compared to influenza, patients with COVID-19 exhibited a continued increase in the white blood SERO cell count, rapid decline of hemoglobin, more rapid increase in blood urea nitrogen HP blood SERO urea nitrogen (BUN) and D-dimer, and higher level of alanine transaminase, C-reactive protein, ferritin, and fibrinogen. Using these results, we sub-classified the COVID-19 patients into 5 clusters through a hierarchical clustering analysis. We then reviewed the medical record of these patients and risk stratified them based on the clinical outcomes. The cluster with the highest risk showed 27.8% fatality, 94% ICU admission, 94% intubation, and 28% discharge rates compared to 0%, 38%, 22%, and 88% in the lowest risk cluster, respectively. Patients in the highest risk cluster had leukocytosis MESHD leukocytosis HP including neutrophilia HP and monocytosis HP, severe anemia MESHD anemia HP, higher BUN, creatinine, D-dimer, alkaline phosphatase, bilirubin, and troponin. Conclusions There are significant differences in the clinical and laboratory courses between COVID-19 and influenza. Risk stratification in hospitalized COVID-19 patients using laboratory data could be useful to predict clinical outcomes and pathophysiology of these patients.

    Urinalysis, but not blood SERO biochemistry, detects the early renal-impairment in patients with COVID-19

    Authors: Haifeng zhou Jr.; Zili Zhang Jr.; Heng Fan Sr.; Junyi Li Jr.; Mingyue Li Jr.; Yalan Dong Jr.; Weina Guo Jr.; Lan Lin Jr.; Zhenyu Kang Jr.; Ting Yu Jr.; Chunxia Tian Jr.; Yang Gui Jr.; Renjie Qin Jr.; Haijun Wang Sr.; ShanShan Luo Sr.; Desheng Hu

    doi:10.1101/2020.04.03.20051722 Date: 2020-04-06 Source: medRxiv

    Background: In December 2019, a novel coronavirus (SARS-CoV-2) caused infectious disease MESHD, termed COVID-19, outbroke in Wuhan, China. COVID-19 patients manifested as lung injury MESHD with complications in other organs, such as liver, heart, gastrointestinal tract, especially for severe cases. However, whether COVID-19 causes significant acute kidney injury MESHD acute kidney injury HP (AKI) remained controversial. Methods: We retrospectively analyzed the clinical characteristics, urine and blood SERO routine tests and other laboratory parameters of hospitalized COVID-19 patients in Wuhan Union Hospital. Findings: 178 patients, admitted to Wuhan Union hospital from February 02 to February 29, 2020, were included in this study. No patient (0 [0%]) presented increased serum SERO creatinine (Scr), and 5 (2.8%) patients showed increased blood urea nitrogen HP blood SERO urea nitrogen (BUN), indicating few cases with kidney dysfunction. However, for patients (83) with no history of kidney disease MESHD who received routine urine test upon hospitalization, 45 (54.2%) patients displayed abnormality in urinalysis, such as proteinuria MESHD proteinuria HP, hematuria MESHD hematuria HP and leukocyturia, while none of the patients was recorded to have acute kidney injury MESHD acute kidney injury HP (AKI) throughout the study. Meanwhile, the patients with abnormal urinalysis usually had worse disease progression MESHD reflecting by laboratory parameters presentations, including markers of liver injury, inflammation MESHD, and coagulation. Conclusion: Many patients manifested by abnormal urinalysis on admission, including proteinuria MESHD proteinuria HP or hematuria MESHD hematuria HP. Our results revealed that urinalysis is better in unveiling potential kidney impairment of COVID-19 patients than blood SERO chemistry test and urinalysis could be used to reflect and predict the disease MESHD severity. We therefore recommend pay more attention in urinalysis and kidney impairment in COVID-19 patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.